Establishment of Gemcitabine-resistant Mouse Pancreatic Ductal Adenocarcinoma Cell Line and Possible Therapeutic Agents
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to gemcitabine (GEM) resistance. This study aimed to establish a clinically relevant immunocompetent model to identify novel mediators of acquired GEM resistance. MATERIALS AND METHODS: GEM selection to establish a line with reduced sensitivity (mPDAC-R). RESULTS: mPDAC-R exhibited sustained growth under GEM treatment, alongside enhanced invasiveness and metastatic potential. Transcriptomic profiling identified monoamine oxidase B (MAOB) as an up-regulated mediator. Pharmacological inhibition of MAOB significantly suppressed proliferation and tumor growth in both mPDAC-R and human PDAC cell lines. CONCLUSION: We established a novel GEM-resistant mPDAC model and identified MAOB as a promising therapeutic target. These findings provide a rationale for targeting MAOB-driven survival signals to overcome chemoresistance in refractory pancreatic cancer.
Fields of Study & Subjects
Pancreatic and Hepatic Oncology Research
Pancreatitis Pathology and Treatment
Cancer
Lipids
and Metabolism
Publication details
- Journal / source
- Anticancer Research
- Volume
- 46
- Issue
- 4
- Pages
- 1819–1831
- Publication date
- 27 March 2026
- Language
- EN